Eli Lilly says closely watched combo obesity regimen boosts weight loss in mid-stage trial
Eli Lilly has partnered with Hims & Hers Health to expand access to its obesity treatments through telehealth, allowing online consultations and home delivery of prescription weight management medications. This partnership aims to increase accessibility to Lilly's obesity treatments, including its recently approved medication Zepbound. The collaboration comes as Lilly continues to develop its obesity portfolio.
Listen to Live Briefing
Real-time synthesized voice briefing Β· Live Feeds Desk
- β Eli Lilly and Company partnered with Hims & Hers Health, Inc. to make two of Lilly's obesity treatments available through the Hims & Hers digital healthcare platform.
- β The partnership allows for online consultations and home delivery of prescription weight management medications.
- β Zepbound is a dual GLP-1/GIP agonist approved by the FDA for chronic weight management in adults with a BMI of 30 or more, or 27 with a weight-related health condition.
What changed
Eli Lilly's partnership with Hims & Hers Health to expand access to its obesity treatments through telehealth is a new development in the company's efforts to increase accessibility to its medications.
Live updates
-
Eli Lilly partners with Hims & Hers for obesity treatment access
Eli Lilly has partnered with Hims & Hers Health to expand access to its obesity treatments through telehealth, allowing online consultations and home delivery of prescription weight management medications. This partnership aims to increase accessibility to Lilly's obesity treatments, including its recently approved medication Zepbound. The collaboration comes as Lilly continues to develop its obesity portfolio.
Why it matters
The partnership between Eli Lilly and Hims & Hers Health is significant as it addresses the growing demand for obesity treatments and increases accessibility to these medications. Eli Lilly's obesity portfolio includes Zepbound, a dual GLP-1/GIP agonist approved by the FDA for chronic weight management in adults with a BMI of 30 or more, or 27 with a weight-related health condition. The company is also testing other treatments, such as eloralintide and Tirzepatide, alone or in combination.
What is confirmed
- Eli Lilly and Company partnered with Hims & Hers Health, Inc. to make two of Lilly's obesity treatments available through the Hims & Hers digital healthcare platform.
- The partnership allows for online consultations and home delivery of prescription weight management medications.
- Zepbound is a dual GLP-1/GIP agonist approved by the FDA for chronic weight management in adults with a BMI of 30 or more, or 27 with a weight-related health condition.
What to watch next
- The outcome of Eli Lilly's ongoing 70-week study testing Bimagrumab and Tirzepatide alone or in combination for adults without type 2 diabetes.
- The performance of eloralintide in future trials, given its 20% weight loss results in mid-stage trials.
- The impact of the partnership on the accessibility and adoption of Eli Lilly's obesity treatments.
confidence 100%Sources used for this update (2)
- finance.yahoo.com β Eli Lilly Partners With Hims & Hers to Expand Access to Obesity Treatments Through Telehealth
- www.speedtest.net β Speedtest Apps: Our internet speed test available across a...
-
Eli Lilly reports 20% weight loss for eloralintide in mid-stage trial
Eli Lilly reports that its amylin-targeting drug eloralintide achieved 20% weight loss in mid-stage trials. This adds to the company's obesity portfolio, which includes Zepbound, a dual GLP-1/GIP agonist approved by the FDA for chronic weight management in adults with a BMI of 30 or more, or 27 with a weight-related health condition. Zepbound outperformed Novo Nordisk's Wegovy in the first head-to-head trial between the two drugs. Lilly is also testing Bimagrumab and Tirzepatide alone or in combination over a 70-week study for adults without type 2 diabetes.
Why it matters
The obesity market is characterized by a competition for market share between Eli Lilly and Novo Nordisk. Lilly's pipeline includes multiple mechanisms, ranging from dual agonists to triple-agonist drugs like retatrutide. These therapies target various hormone receptors to induce weight loss.
What is confirmed
- The FDA approved Zepbound for chronic weight management in adults with a BMI of 30 or more, or 27 with at least one weight-related health condition.
- Zepbound beat Novo Nordisk's Wegovy in the first head-to-head trial comparing the two obesity drugs.
Still unconfirmed
- The amylin-targeting drug eloralintide produced 20% weight loss in mid-stage trials.
- A 70-week study is evaluating the efficacy and safety of Bimagrumab and Tirzepatide alone or in combination.
What to watch next
- Phase 3 trial results for eloralintide
- Results of the Bimagrumab and Tirzepatide combination study
confidence 90%Sources used for this update (5)
- pharmaphorum.com β Zepbound tops Wegovy in first head-to-head weight-loss trial
- pharmaphorum.com β Lilly reports 20% weight loss with amylin-targeting drug
- pharmaphorum.com β Lilly gets FDA okay for tirzepatide as obesity therapy
- finance.yahoo.com β Eli Lilly Seen Sustaining Obesity Growth, UBS Says
- ctv.veeva.com β A Study to Investigate Weight Management With Bimagrumab ...
-
Eli Lilly Trial Shows Retatrutide Reduces Sleep Apnea and Weight
Eli Lilly's experimental triple-agonist drug retatrutide has produced up to 28.7% weight loss in Phase 3 trials for adults with overweight and obesity. Two Phase 3 trials also showed that retatrutide significantly reduced sleep apnea severity and apnea episodes compared to a placebo. The drug targets three hormone receptors simultaneously. Physicians have compared the magnitude of the results to surgical operations. Clinical evaluations continue as the pipeline tracker places the investigational medicine in Phase 3 development for participants with or without comorbid type 2 diabetes.
Why it matters
Pharmaceutical developers are shifting focus from single-hormone treatments toward multi-receptor agonists to improve efficacy for metabolic conditions. Retatrutide represents this class by engaging three distinct hormone receptors at once. Previous mid-stage findings demonstrated strong weight reduction, prompting broader Phase 3 testing across diverse patient populations.
What is confirmed
- Retatrutide targets three hormone receptors at once and has produced up to 28.7% weight loss in Phase 3 trials.
- In two Phase 3 trials, retatrutide significantly reduced sleep apnea severity and apnea episodes in adults with overweight and obesity.
Still unconfirmed
- Some doctors are comparing the trial results to the operating room.
What to watch next
- Further Phase 3 trial results and regulatory updates regarding retatrutide
- Published participant experiences involving appetite, mobility, and daily life
confidence 90%Sources used for this update (7)
- onthepen.com β Retatrutide β Pipeline Tracker | On The Pen
- welltica.com β Eli Lillyβs next shot after Ozempic hit about 60 pounds in ...
- www.healthspectra.com β Retatrutide: What Eli Lilly's New Weight Loss Drug Could Do
- www.medscape.com β Investigational Med Tied to Major Reduction in OSA Severity
- kures.co β Retatrutide Results: What Trial Participants Experienced
- www.prnewswire.com β Eli Lilly and Company News and Press Releases | PR Newswire
- gizmodo.com β The Most Powerful Obesity Drug Yet Has a Hidden ... - Gizmodo
-
Eli Lilly combination drug EloraTZP shows 23.3% weight loss in Phase 2b trial
Eli Lilly reported that its experimental combination drug EloraTZP achieved an average weight loss of 23.3% over 48 weeks in a Phase 2b trial of 367 adults with obesity or overweight and type 2 diabetes. This outperformed tirzepatide alone, which saw 14.8% weight loss. However, the treatment faced tolerability issues, with up to 27% of participants discontinuing the drug due to adverse events. These results reflect Lilly's broader strategy to move beyond single-hormone GLP-1 medications toward multi-receptor agonists to increase efficacy.
Why it matters
The company is developing triple-action drugs like retatrutide to target three hormone receptors simultaneously, contrasting with the one or two receptors targeted by semaglutide and tirzepatide. Eli Lilly and Novo Nordisk are also exploring amylin-targeting drugs to complement existing obesity treatments. These efforts aim to maintain market leadership in the competitive diabetes and weight-loss sector.
What is confirmed
- EloraTZP produced a 23.3% average weight loss over 48 weeks compared to 14.8% for tirzepatide alone in a trial of 367 adults.
- Up to 27% of combination treatment recipients stopped the drug because of adverse events.
- Retatrutide is a triple receptor agonist designed to treat obesity and type 2 diabetes.
- Retatrutide activates three hormone receptors, while tirzepatide targets two and semaglutide targets one.
Still unconfirmed
- Eli Lilly stocks traded up by 3.96 percent on optimism regarding obesity drug developments.
- RBC analysts believe the company will raise its full-year revenue outlook based on third-quarter sales momentum.
What to watch next
- Eli Lilly earnings report on October 29
- Phase III TRIUMPH-2 trial results for retatrutide
- FDA regulatory filings for EloraTZP or retatrutide
confidence 95%Sources used for this update (10)
- scitechdaily.com β Beyond Ozempic? New Weight Loss Drug Shows Stunning Results ...
- rocketnews.com β Why Lilly and Novo are betting on amylin to power a new wave ...
- finance.yahoo.com β This Drug Combination for Eli Lilly Generated Significantly ...
- medicalxpress.com β Triple-action drug retatrutide delivers major weight loss for ...
- www.trialsitenews.com β Lilly's Triple-Action Diabetes Treatment Delivers 23% Weight ...
- www.mogazmasr.com β Retatrutide and Lillyβs new weight-loss data lift hopes, but ...
- www.biospace.com β Weight loss - BioSpace
- www.timothysykes.com β Eli Lilly (LLY) Extends Obesity Drug Lead As Wall Street ...
- www.yahoo.com β What is retatrutide and when could weight-loss drug be ...
- www.fool.com β Eli Lilly Reports Earnings on Oct. 29. Here's Why the ...
-
Eli Lilly Combination Drug Boosts Weight Loss
Eli Lilly faces high discontinuation rates alongside significantly greater weight loss from its combined regimen of tirzepatide and eloralintide compared to tirzepatide alone, according to mid-stage trial results. The pharmaceutical company is actively pursuing superior weight loss treatments beyond its current GLP-1 medications, driven by strong market sales in its diabetes and weight-loss portfolios. Financial analysts at RBC indicate the company is likely to raise its full-year revenue outlook based on ongoing third-quarter sales momentum.
Why it matters
The company continues to seek more effective therapeutic options to build upon the commercial success of existing treatments such as Zepbound. However, elevated discontinuation rates in the mid-stage trial present a clinical challenge that must be balanced against the enhanced efficacy of the dual-drug approach. RBC notes that robust sales in diabetes and weight-loss drugs position the company well for potential upward revisions to its financial guidance.
What is confirmed
- Eli Lilly's combination regimen of tirzepatide and eloralintide produced significantly more weight loss than just Zepbound in a mid-stage trial, though discontinuation rates were also far higher.
- RBC says Eli Lilly is likely to raise its full-year revenue outlook due to strong diabetes and weight-loss drug sales.
What to watch next
- Phase 3 trial initiations scheduled by the end of 2026
- Official full-year revenue outlook updates from Eli Lilly
confidence 90%Sources used for this update (4)
- www.biospace.com β Obesity - BioSpace
- finance.yahoo.com β This Drug Combination for Eli Lilly Generated Significantly More Weight Loss Than Just Zepbound, but Discontinuation Rates Were Also Far Higher. Here's What This Could Mean for ...
- www.fool.com β This Drug Combination for Eli Lilly Generated Significantly ...
- finance.yahoo.com β Eli Lilly Likely to Raise Revenue Outlook Amid Strong Diabetes, Weight-Loss Drug Sales, RBC Says
-
Eli Lilly's combo obesity regimen boosts weight loss in mid-stage trial
Eli Lilly's combination regimen of tirzepatide and eloralintide resulted in significant weight loss in adults with obesity and type 2 diabetes. The treatment produced greater weight loss than tirzepatide alone. Eli Lilly plans to initiate Phase 3 trials by the end of 2026.
Why it matters
The company's progress on obesity treatments is closely watched as the global obesity crisis continues to strain healthcare systems. Tirzepatide and eloralintide are being studied for their potential to treat obesity and related conditions. Eli Lilly's plans for Phase 3 trials indicate a significant step forward in developing new treatments.
What is confirmed
- Eli Lilly's combination regimen of tirzepatide and eloralintide resulted in significant weight loss in adults with obesity and type 2 diabetes.
- The treatment produced greater weight loss than tirzepatide alone.
- Eli Lilly plans to initiate Phase 3 trials by the end of 2026.
What to watch next
- Results of Phase 3 trials
- Eli Lilly's plans for regulatory submissions
- Comparative efficacy of tirzepatide and eloralintide versus existing obesity treatments
confidence 100%Sources used for this update (4)
- www.speedtest.net β Speedtest by Ookla - The Global Broadband Speed Test
- www.speedtest.net β Speedtest di Ookla - Il test globale per la velocitΓ della tua...
- intelligence.speedtest.net β Speedtest Intelligence
- ciscoconnect.speedtest.net β Speedtest.net
-
Eli Lilly's combo obesity regimen boosts weight loss in mid-stage trial
Eli Lilly's combination regimen of tirzepatide and eloralintide resulted in significant weight loss in adults with obesity and type 2 diabetes. The treatment, called EloraTZP, produced greater weight loss than tirzepatide alone. Eli Lilly plans to initiate Phase 3 trials by the end of 2026.
Why it matters
The development is a positive step for Eli Lilly's obesity treatment pipeline. Obesity and type 2 diabetes are major health concerns globally, and new treatments are in high demand. Eli Lilly is competing with other pharmaceutical companies, such as Novo Nordisk, to bring effective obesity treatments to market.
What is confirmed
- Eli Lilly's combination regimen of tirzepatide and eloralintide resulted in an average weight loss of 23.3% in adults with obesity and type 2 diabetes over 48 weeks.
- The treatment combines two medicines being studied by Eli Lilly: eloralintide and tirzepatide.
- Eli Lilly plans to initiate Phase 3 trials by the end of 2026.
Still unconfirmed
- Retatrutide, a triple-hormone agonist, showed 28.3% weight loss in a Phase 3 trial.
What to watch next
- Phase 3 trial results for EloraTZP
- Comparison trials with other obesity treatments, such as Wegovy
- Eli Lilly's regulatory submissions for EloraTZP
confidence 85%Sources used for this update (7)
- knowridge.com β New Drug Combo Helps People Lose Up to 23% of Body Weight
- www.advisory.com β Around the nation: Eli Lilly's new obesity drug combo boosts ...
- pharmaphorum.com β More data backs Zepbound over Wegovy for weight loss
- rocketnews.com β Eli Lilly says closely watched combo obesity regimen boosts ...
- worldattention.com β Eli Lillyβs retatrutide and combo drugs show record weight ...
- www.matterfact.com β Retatrutide Hits 28% Weight Loss and Lilly's Amylin Combo ...
- peptidelibrary.io β Retatrutide (GLP-3): Trials, Side Effects & Legal Status
-
Eli Lilly's combo obesity regimen shows promise in mid-stage trial
Eli Lilly's combination regimen of tirzepatide and eloralintide resulted in an average weight loss of 23.3% in adults with obesity and type 2 diabetes over 48 weeks, outperforming tirzepatide 15 mg alone. The company plans to initiate Phase 3 trials by the end of 2026. This development is a positive step for Eli Lilly's obesity treatment pipeline.
Why it matters
The global obesity treatment market is highly competitive, with several pharmaceutical companies investing heavily in research and development. Eli Lilly's tirzepatide, a dual GIP/GLP-1 receptor agonist, has already shown significant promise in clinical trials. The addition of eloralintide, an experimental amylin drug, may offer a new treatment option for patients with obesity and type 2 diabetes.
What to watch next
- Eli Lilly's Phase 3 trial initiation
- FDA approval status
- market competition
confidence 0%Sources used for this update (9)
- www.gotquestions.org β Who was Eli in the Bible? - GotQuestions.org
- elireview.com β Eli Review
- www.christianity.com β Who Was Eli in the Bible? His Life and Story - Christianity
- www.eli.org β ELI Home | Environmental Law Institute
- biblehub.com β Topical Bible: Eli
- en.wikipedia.org β Eli (2019 film) - Wikipedia
- en.wikipedia.org β Eli (biblical figure) - Wikipedia
- www.youtube.com β Eli | Official Trailer | Netflix - YouTube
- www.technologyreview.com β Weight-loss drugs show signs of slowing biological aging, say drugmakers
-
Eli Lilly combo drug EloraTZP beats tirzepatide in mid-stage trial
Eli Lilly reported that EloraTZP, a combination of tirzepatide and the experimental amylin drug eloralintide, outperformed tirzepatide 15 mg in a 48-week Phase 2 trial. The study involved adults with obesity and type 2 diabetes, showing that patients lost an average of 23.3% of their body weight and saw improved A1C reduction compared to tirzepatide alone. Following these positive results, the company intends to launch Phase 3 trials for the combination regimen by the end of 2026.
Why it matters
The obesity market is highly competitive, with Eli Lilly and Novo Nordisk facing new challenges from Roche's experimental drug enicepatide. Lilly is also developing retatrutide, another potent weight-loss candidate. These efforts aim to establish a new high-water mark for efficacy in weight reduction and metabolic health.
What is confirmed
- EloraTZP is a combination of the drug tirzepatide and the experimental amylin drug eloralintide.
- In a 48-week Phase 2 trial, EloraTZP delivered greater weight loss and A1C reduction than tirzepatide 15 mg in adults with obesity and type 2 diabetes.
- Patients using EloraTZP lost an average of 23.3% of their body weight.
- Eli Lilly plans to start Phase 3 trials for the eloralintide and tirzepatide combo by the end of the year.
- Roche's experimental drug enicepatide helped overweight or obese patients with type 2 diabetes lose an average of 15.5% of their body weight in a mid-stage trial.
Still unconfirmed
- Some patients using an emerging drug lost up to a quarter of their body weight.
- People with type 2 diabetes lost up to 60 pounds on Lilly's latest weight loss drug.
- Lilly's retatrutide GLP-1 delivers an average weight loss of 50 pounds.
What to watch next
- Launch of Phase 3 trials for EloraTZP at the end of 2026
- Release of full Phase 3 data for retatrutide
confidence 100%Sources used for this update (20)
- finance.yahoo.com β Can Rocheβs Latest Obesity Drug Results Help it Challenge Eli Lilly and Novo Nordisk?
- Ars Technica β Most powerful obesity drug yet: People lost up to 25% of weight in trial
- The Guardian β βGodzillaβ of weight-loss drugs could provide other important health benefits
- Reuters β Lilly's experimental drug cuts weight by 21% in diabetes trial
- Scientific American β Blockbuster retatrutide trial signals a βnew high-water markβ for weight-loss drugs
- NBC News β People with Type 2 diabetes lost up to 60 pounds on Lillyβs latest weight loss drug
- Fierce Biotech β Lilly sets up next-gen obesity battle with full phase 3 retatrutide data
- CNBC β Eli Lilly says closely watched combo obesity regimen boosts weight loss in mid-stage trial
- Eli Lilly β Lilly's EloraTZP (combination of eloralintide and tirzepatide) delivered greater weight loss and A1C reduction vs. tirzepatide 15 mg in adults with obesity and type 2 diabetes
- USA Today β Lilly's retatrutide GLP-1 delivers average weight loss of 50 pounds
- Fierce Biotech β Lilly raises diabetes weight-loss bar with amylin-Zepbound combo
- Yahoo β Emerging drug helps some patients lose up to quarter of body weight
Community Sentiment: How do you assess this situation?
Voice your perspective Β· Real-time aggregated sentiment from the Live Feeds community